SCHEMBL1627422

SCHEMBL1627422

CC(C)(C(=O)O)c1ccc(Cl)c(F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.63
AKR1C2 P52895 2/20 0.63
APP P05067 1/20 0.56
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
SLC22A12 Q96S37 1/20 0.40
MAP4K4 O95819 1/20 0.39
PTGDR Q13258 1/20 0.38
KMO O15229 2/20 0.38
LTB4R Q15722 2/20 0.37
LTB4R2 Q9NPC1 2/20 0.37
ERCC5 P28715 1/20 0.37
FEN1 P39748 1/20 0.37
POLB P06746 1/20 0.37
APEX1 P27695 1/20 0.37
AR P10275 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626272 0.86 AKR1C3 (0.63) AKR1C3AKR1C2APPCYP3A4CYP2C9
SCHEMBL29009905 0.84 AKR1C2 (0.47) AKR1C3AKR1C2APPCYP3A4CYP2C9
SCHEMBL1627216 0.83 AKR1C3 (0.64) AKR1C3AKR1C2APPCYP3A4CYP2C9
SCHEMBL1626481 0.83 AKR1C3 (0.51) AKR1C3AKR1C2APPSLC22A12MAP4K4
SCHEMBL2547140 0.82 AKR1C3 (0.71) AKR1C3AKR1C2APPCYP3A4CYP2C9
SCHEMBL1626715 0.81 CNR1 (0.48) AKR1C3AKR1C2APPCYP3A4CYP2C9
SCHEMBL31292258 0.80 APP (0.58) AKR1C3AKR1C2APPCYP3A4CYP2C9
SCHEMBL17420777 0.80 AKR1C3 (0.42) AKR1C3AKR1C2APPSLC22A12KMO
SCHEMBL30628282 0.80 AKR1C3 (0.42) AKR1C3AKR1C2APPSLC22A12KMO
SCHEMBL3179071 0.80 CYP2C9 (0.46) AKR1C3AKR1C2APPCYP2C9KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN AKR1C3 382/4885AKR1C2 272/4885APP 2779/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN AKR1C3 382/4885AKR1C2 272/4885APP 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.